Published the interim financial summary for the second quarter of the fiscal year ending March 2027. Net sales were 45,503 million yen, down -0.7% year-over-year, and interim net income attributable to owners of parent was 5,191 million yen, down -33.3% year-over-year. Full-year outlook is expected to be revised downward to net sales of 89,000 million yen and net income of 10,000 million yen (reflecting the earnings impact related to Tabneos).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4547","jir_company_name":"Kissei Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4547-20261104-01.pdf","jir_short_summary":"Published the interim financial summary for the second quarter of the fiscal year ending March 2027. Net sales were 45,503 million yen, down -0.7% year-over-year, and interim net income attributable to owners of parent was 5,191 million yen, down -33.3% year-over-year. Full-year outlook is expected to be revised downward to net sales of 89,000 million yen and net income of 10,000 million yen (reflecting the earnings impact related to Tabneos).","jir_summary":"### Overview of Results\nThis financial summary reports consolidated results for the second quarter of the fiscal year ending March 2027. Net sales were 45,503 million yen (Year-over-Year -0.7%), operating income was 1,694 million yen, ordinary income was 2,923 million yen, and interim net income attributable to owners of parent was 5,191 million yen (Year-over-Year -33.3%). Segment contributions for the interim period were primarily driven by the pharmaceutical business. The full-year earnings forecast assumes net sales of 89,000 million yen and net income of 10,000 million yen, but note that revisions upward or downward are possible given impacts including special gains\/losses related to Tabneos.\n\n### Outlook and Capital Policy Background\nThe current environment remains challenging due to factors such as drug price revisions, and exchange rate and interest rate movements may affect performance. The full-year forecast for the fiscal year ending March 2027 will be revised after reassessing Tabneos prospects, combining reductions and increases focused on certain products. The financial summary also explains share-related actions, such as treasury stock acquisitions and disposal of restricted shares, and the financial position remains solid with a shareholders' equity ratio of 85.5%.","jir_financial_highlights":"Net Sales: 45,503 (Year-over-Year -0.7%)\nOperating Income: 1,694 (Year-over-Year -)\nOrdinary Income: 2,923 (Year-over-Year -)\nInterim Net Income Attributable to Owners of Parent: 5,191 (Year-over-Year -33.3%)\nNet Income per Share: 124.88 (Year-over-Year -)","jir_category":"","jir_hashtags":"#KisseiPharmaceutical, #FinancialSummary, #Interim, #SegmentSales, #DrugPricingSystem","jir_key_figures":"Net Sales: 45,503 million yen (Year-over-Year -0.7%)\nOperating Income: 1,694 million yen\nInterim Net Income Attributable to Owners of Parent: 5,191 million yen (Year-over-Year -33.3% decline)","jir_meta_title":"Kissei Pharmaceutical Co., Ltd. Q2 FY2027 Financial Summary | Net Sales 45,503 million yen, Net Income 5,191 million yen","jir_meta_description":"Summary of Kissei Pharmaceutical Co., Ltd.'s financial results for Q2 of FY2027. Covers net sales and profit figures, year-over-year comparisons, current full-year outlook and key points, and segment trends.","jir_og_title":"Kissei Pharmaceutical Co., Ltd. Q2 Financial Summary | Net Sales 45,503 million yen","jir_og_description":"Kissei Pharmaceutical Co., Ltd. Q2 FY2027 financial summary. Net sales were 45,503 million yen and net income was 5,191 million yen. Also addresses points on the full-year outlook revision.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/4\\\",\\\"2026\/7\\\",\\\"2026\/9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[45831,45503,45503],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/4\\\",\\\"2026\/7\\\",\\\"2026\/9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[-6837,1694,1694],\\\"borderColor\\\":\\\"#8e5ea2\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"net_income_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Interim Net Income Attributable to Owners of Parent Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/4\\\",\\\"2026\/7\\\",\\\"2026\/9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Interim Net Income\\\",\\\"data\\\":[7784,5191,5191],\\\"borderColor\\\":\\\"#3cba9f\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"assets_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Assets Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Current Assets\\\",\\\"Fixed Assets\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Total Assets\\\",\\\"data\\\":[110,955?],\\\"backgroundColor\\\":\\\"#42a5f5\\\"}]},\\\"options\\\":{}}\"}]","ir_related_company":8930,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-141385","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n